UK markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
162.24+1.85 (+1.15%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close160.39
Open161.34
Bid162.00 x 1800
Ask162.22 x 1200
Day's range160.56 - 162.51
52-week range133.65 - 173.65
Volume9,049,432
Avg. volume8,203,358
Market cap427.131B
Beta (5Y monthly)0.72
PE ratio (TTM)29.44
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.04 (2.49%)
Ex-dividend date22 Feb 2021
1y target estN/A
All
News
Press releases
  • TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress
    Business Wire

    TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress

    Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announced results from the Phase 3b TRITON trial, the first randomised controlled study evaluating the efficacy and safety of initial triple oral combination therapy (UPTRAVI® [selexipag], OPSUMIT® [macitentan] and tadalafil) compared to initial double oral combination therapy (placebo, macitentan and tadalafil) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension (PAH). Study results were featured as an oral presentation as part of the digital European Society of Cardiology Congress held 29 August – 1 September 2020.